Abstract PD7-02: Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: J. Gomez Tejeda Zanudo, S. Kirschner, A. Patel, E. Christoforou, A. Barkell, J. Baginska, B. Binboga Kurt, B. Koca, O. Cunningham, C. Stever, T. Parker, T. Rahman, B. Cross, H. Rimmer, T. Carr, M. Luo, I. Martino, B. Drummey, S. A. Virani, K. Santos, J. Bsat, C. Snow, N. Tung, S. Lo, M. Faggen, N. Sinclair, N. Ahmad, M. Constantinou, S. Sinclair, J. L. Meisel, T. A. King, J. L. Guerriero, E. A. Mittendorf, N. U. Lin, E. P. Winer, E. C. de Bruin, S. M. Tolaney, A. Moeini, A. C. Garrido-Castro
Institutions: Dana-Farber Cancer Institute, AstraZeneca (United Kingdom), Beth Israel Deaconess Medical Center, Stamford Hospital, Berkshire Medical Center, Brown University, Emory University, Winship Cancer Institute, Dana-Farber Brigham Cancer Center, Yale Cancer Center, Yale University, AstraZeneca (Spain)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129304614